Debiopharm International SA Strengthens Compliance and Clinical Trial Oversight with Veeva Vault eTMF
Veeva Systems (NYSE: VEEV) announced today that Debiopharm International SA, part of Swiss-based biopharmaceutical company Debiopharm Group™, selected Veeva Vault eTMF to improve oversight across its trial master file (TMF) processes and work closely with contract research organizations (CROs) by collaborating on a single, cloud-based application.
“Veeva is helping us streamline our clinical operations,” said Christian A. Aeschlimann, director of clinical operations at Debiopharm. “Veeva Vault eTMF will help us maintain an always-accurate, up-to-date TMF and align with external partners by working in the same system.”
As a sponsor, Debiopharm is required by ICH E6(R2) to maintain oversight throughout clinical trials. External partners were unable to access the company's previous, on-premise eTMF, so CROs used their own systems and transferred documents periodically. This meant that Debiopharm did not have full, real-time visibility into the CROs’ TMF activities.
Veeva Vault eTMF provides a single source of truth for trial documentation. Sponsors and CROs can manage TMF documents and processes in the same system, in real-time, as they are being executed. Now Debiopharm can keep its TMF in a constant state of inspection readiness and ensure partners adhere to its standard operating procedures.
“In our quest for continuous improvement, we selected Veeva Vault eTMF to help us work more efficiently and maintain high quality trial documentation,” said Vincent Demeautis, clinical operations manager at Debiopharm. “Sharing a single system with CROs to drive all TMF processes will eliminate the need to manage and reconcile multiple TMF sources while improving our responsiveness and collaboration with external and internal study team members.”
Veeva Vault eTMF will also provide Debiopharm with reports and dashboards for visibility into TMF completeness, timeliness, and accuracy. This will help the company to check the status and quality of documentation and proactively resolve any issues that arise.
"Veeva Vault eTMF was the best solution on the market to meet our current and future needs," said Sofie Lemmens, senior clinical trial associate at Debiopharm, who led the implementation of Veeva Vault eTMF. "It was a critical investment across our internal teams to improve TMF quality and access."
By adopting Veeva Vault eTMF, Debiopharm has taken its first step toward a unified clinical model to streamline end-to-end processes and systems, increase collaboration, and improve performance across trials. This reflects an industrywide shift, with nearly all (99%) respondents to the Veeva 2017 Unified Clinical Operations Survey reporting the need to unify their clinical operations.
“Sponsors are unifying systems and processes to improve study quality and execution while managing a growing number of trials and increasing complexity across the clinical lifecycle,” said Rik Van Mol, vice president, R&D Strategy, Europe at Veeva. “Veeva Vault eTMF lets Debiopharm improve trial visibility and compliance as well as begin a journey toward unified clinical operations.”
Veeva Vault eTMF is part of Veeva Vault Clinical Suite, the industry's first suite of applications that combines eTMF with EDC, CTMS, and study start-up to unify clinical data management and operations. To learn how organizations are eliminating system silos across clinical operations with Veeva Vault Clinical Suite, visit veeva.com/eu/Clinical.
For more on Veeva Vault eTMF, visit: veeva.com/eu/eTMF
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 600 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com/eu.
About Debiopharm International SA
Part of Debiopharm Group™ – a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management – Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. For more information, please visit debiopharm.com or follow @DebiopharmNews on Twitter.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-K for the period ended January 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
Veeva Systems Inc.
+44 (0) 7715 817589
+44 (0) 7746 546773
Debiopharm International SA
Christelle von Büren
+41 (0)21 321 01 11
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Andersen Global Expands UK Locations23.5.2019 16:30:00 EEST | Tiedote
Claritas Tax Limited, a Birmingham, United Kingdom-based collaborating firm of Andersen Global, has opened a new office location in Deansgate, Manchester city center. This means that Andersen Global now has a presence in six locations in the UK through its member firms and collaborating firms. “Now more than ever, it’s important that businesses have easy access to quality advice in the UK’s dynamic political and business environment. The addition of another location in the region adds to our existing capabilities and will allow us to continue providing best-in-class service,” said Mark Vorsatz, Andersen Global Chairman and CEO of Andersen Tax LLC. Founded in 2012, Claritas Tax Limited has a list of clientele from entrepreneurial, privately owned, venture capital, and private equity owned businesses, listed companies and stakeholders. Claritas provides a broad range of tax consulting services, including all aspects of M&A and transactional taxes, R&D and Intellectual Property claims, sh
Mindbreeze Receives Attestation in Accordance with BSI Cloud Requirements23.5.2019 16:11:00 EEST | Tiedote
Mindbreeze receives attestation for its Mindbreeze InSpire SaaS service according to the specifications of the C5 catalogue of requirements (Cloud Computing Compliance Controls Catalogue, abbreviated C5), published by the German Federal Office for Information Security (BSI). The Mindbreeze InSpire SaaS service is professionally operated in Mindbreeze data centers on behalf of the customers. The attestation was issued by KPMG Alpen-Treuhand GmbH Wirtschaftsprüfungs- und Steuerberatungsgesellschaft. “The number of cloud services in the field of data analysis is growing steadily. This makes it all the more essential for customers to take a closer look at the choice of suppliers. C5 provides the regulatorily defined IT security level, which is comparable to the IT basic protection level that is increased by cloud controls,” explains Klaus Schatz, Managing Director of KPMG Advisory GmbH. C5 attestation (ISAE 3000 Report Type 2) is a recognized and authoritative verification for all customer
Bacardi Limited Announces 5th Annual Good Spirited Awards for Employee-Led Global Environmental Sustainability Programs23.5.2019 15:15:00 EEST | Tiedote
In continuation of its ongoing sustainability efforts, Bacardi Limited is proud to announce the recipients of its 5th annual Bacardi Limited Good Spirited Awards. Launched in 2014, the awards recognize the employees, teams and facilities across the company’s global network that developed the best environmental programs across five different categories: Production Facility, Brand Innovation, Sustainable Office, Green Champions or Partnerships. This year’s winners instituted programs to shift to renewable energy, reduce water use and waste, increase recycling efforts and amplify the Bacardi Limited No Straws campaign to decrease the amount of single-use plastic straws by one billion over the next two years. The awards acknowledge activities that took place between April 1, 2018 and March 31, 2019. “Bacardi Limited’s Good Spirited Awards truly underscore the company’s foundation and support of global environmental sustainability efforts at our facilities and in our communities,” says Rick
Teridion Announces Deep Integration with Cisco Meraki MX Security and SD-WAN Appliances to Deliver New High Performance Internet Service23.5.2019 15:00:00 EEST | Tiedote
Teridion, the company delivering the only global public cloud-based WAN service, today announced its deep integration with Cisco Meraki MX Security and SD-WAN appliances. The combined solution is a bold new approach to branch networking, delivering the industry-leading Auto VPN and SD-WAN capabilities of Cisco Meraki’s MX appliances with Teridion’s high throughput and low latency public cloud-based WAN service. For the first time, enterprises can take advantage of a WAN solution that has visibility and control of first, middle, and last mile of the Internet and extends SD-WAN and WAN acceleration beyond enterprise sites to include SaaS applications and enterprise cloud workloads across multiple public cloud providers. Today’s announcement highlights the new, seamless network level integration between Teridion’s high performance cloud WAN service and Cisco Meraki’s easy-to-use Auto VPN routing and high availability capabilities. Enterprise of all sizes can expect real-time applications
C.H. Robinson Acquires Dema Service S.p.A. to Expand Global Presence23.5.2019 14:00:00 EEST | Tiedote
C.H. Robinson (NASDAQ: CHRW) continues to expand its global footprint with its announcement of the acquisition of Dema Service S.p.A. (Dema Service) on May 22, 2019. Dema Service is a leading provider of European road transportation based in Italy. “The acquisition of Dema Service is an exciting milestone for C.H. Robinson and will strengthen our existing footprint in Italy, one of the largest road transportation markets in Europe,” said Jeroen Eijsink, President of Europe for C.H. Robinson. “We are eager to work with Dema Service’s customers to offer our full suite of logistics services to help improve their supply chains.” This is the second European acquisition for C.H. Robinson in 2019. The company recently acquired the freight forwarding group Space Cargo, which expanded C.H. Robinson’s presence in Spain and Columbia. Dema Service is a privately-owned logistics company providing road transportation services across Europe. Headquartered in Pescara, Italy, Dema Service has approxima
Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform23.5.2019 13:30:00 EEST | Tiedote
Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/ FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire) Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market. LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manua
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme